688382 益方生物
已收盘 07-29 15:00:00
资讯
新帖
简况
7月29日益方生物-U涨5.10%,汇添富医疗服务灵活配置混合A基金重仓该股
证券之星 · 08:18
7月29日益方生物-U涨5.10%,汇添富医疗服务灵活配置混合A基金重仓该股
益方生物-U涨5.10%,太平洋三个月前给出“买入”评级,目前股价已超目标价
证券之星 · 08:18
益方生物-U涨5.10%,太平洋三个月前给出“买入”评级,目前股价已超目标价
历史新高!中际旭创股价突破200元
东方财富 · 04:40
历史新高!中际旭创股价突破200元
益方生物-U涨5.21% 医保谈判预期博弈加剧
智选洞察 · 02:02
益方生物-U涨5.21% 医保谈判预期博弈加剧
每周股票复盘:益方生物(688382)一致行动协议解除及权益变动
证券之星 · 07-26 22:16
每周股票复盘:益方生物(688382)一致行动协议解除及权益变动
益方生物-U股价下跌2.24% 控股股东一致行动关系解除
金融界 · 07-24
益方生物-U股价下跌2.24% 控股股东一致行动关系解除
上证580指数上涨1.3%,前十大权重包含内蒙一机等
金融界 · 07-24
上证580指数上涨1.3%,前十大权重包含内蒙一机等
益方生物:控股股东、实际控制人的一致行动人解除一致行动协议
格隆汇 · 07-24
益方生物:控股股东、实际控制人的一致行动人解除一致行动协议
益方生物-U股价小幅回落 生物医药板块活跃度提升
金融界 · 07-22
益方生物-U股价小幅回落 生物医药板块活跃度提升
上证580指数上涨1.17%,前十大权重包含益方生物等
金融界 · 07-21
上证580指数上涨1.17%,前十大权重包含益方生物等
每周股票复盘:益方生物(688382)5笔大宗交易折价12.99%
证券之星 · 07-19
每周股票复盘:益方生物(688382)5笔大宗交易折价12.99%
7月18日益方生物-U涨6.38%,平安医疗健康混合A基金重仓该股
证券之星 · 07-18
7月18日益方生物-U涨6.38%,平安医疗健康混合A基金重仓该股
益方生物-U涨6.38%,太平洋二个月前给出“买入”评级,目前股价已超目标价
证券之星 · 07-18
益方生物-U涨6.38%,太平洋二个月前给出“买入”评级,目前股价已超目标价
益方生物1631万股限售股将于7月25日流通
财中社 · 07-17
益方生物1631万股限售股将于7月25日流通
益方生物-U涨5.00% 资金博弈与事件共振驱动估值波动
智选洞察 · 07-17
益方生物-U涨5.00% 资金博弈与事件共振驱动估值波动
贝达药业:公司与益方生物尚无其他应披露而未披露的合作事项
证券之星 · 07-16
贝达药业:公司与益方生物尚无其他应披露而未披露的合作事项
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
DoNews · 07-16
科创成长层改革推进 券商系统升级及风险揭示书签署有序展开
7月15日益方生物现5笔折价12.99%的大宗交易 合计成交4920.83万元
证券之星 · 07-15
7月15日益方生物现5笔折价12.99%的大宗交易 合计成交4920.83万元
益方生物-U涨5.15%创历史新高 资金博弈与研发进展推动股价上行
智选洞察 · 07-15
益方生物-U涨5.15%创历史新高 资金博弈与研发进展推动股价上行
医药主题基金首批二季报出炉!这只产品规模环比增30倍
北京商报官方账号 · 07-14
医药主题基金首批二季报出炉!这只产品规模环比增30倍
加载更多
公司概况
公司名称:
益方生物科技(上海)股份有限公司
所属行业:
医药制造业
上市日期:
2022-07-25
主营业务:
益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。
发行价格:
18.12
{"stockData":{"symbol":"688382","market":"SH","secType":"STK","nameCN":"益方生物","latestPrice":47,"timestamp":1753772400000,"preClose":44.72,"halted":0,"volume":11645647,"delay":0,"changeRate":0.051,"floatShares":418000000,"shares":578000000,"eps":-0.371,"marketStatus":"已收盘","change":2.28,"latestTime":"07-29 15:00:00","open":45,"high":48.99,"low":44.06,"amount":547000000,"amplitude":0.1102,"askPrice":47.19,"askSize":5,"bidPrice":47,"bidSize":274,"shortable":0,"etf":0,"ttmEps":-0.371,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753839000000},"marketStatusCode":5,"adr":0,"adjPreClose":44.72,"symbolType":"stock_kcb","openAndCloseTimeList":[[1753752600000,1753759800000],[1753765200000,1753772400000]],"highLimit":49.19,"lowLimit":40.25,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":578327844,"isCdr":false,"pbRate":15.35,"roa":"--","roe":"--","epsLYR":-0.4167,"committee":0.848214,"marketValue":27181000000,"turnoverRate":0.0279,"status":0,"afterMarket":{"amount":0,"volume":0,"close":47,"buyVolume":0,"sellVolume":0,"time":1753774438021,"indexStatus":"已收盘 07-29 15:30:00","preClose":44.72},"floatMarketCap":19628000000},"requestUrl":"/m/hq/s/688382","defaultTab":"news","newsList":[{"id":"2555035554","title":"7月29日益方生物-U涨5.10%,汇添富医疗服务灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035554","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035554?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:18","pubTimestamp":1753777120,"startTime":"0","endTime":"0","summary":"证券之星消息,7月29日益方生物-U涨5.10%创60日新高,收盘报47.0元,换手率2.79%,成交量11.65万手,成交额5.47亿元。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共127家,其中持有数量最多的公募基金为汇添富基金的汇添富医疗服务灵活配置混合A。汇添富医疗服务灵活配置混合A目前规模为29.15亿元,最新净值1.947,较上一交易日上涨3.4%,近一年上涨68.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900026300.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2555035660","title":"益方生物-U涨5.10%,太平洋三个月前给出“买入”评级,目前股价已超目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2555035660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555035660?lang=zh_cn&edition=full","pubTime":"2025-07-29 16:18","pubTimestamp":1753777108,"startTime":"0","endTime":"0","summary":"今日益方生物-U涨5.10%,收盘报47.0元。2025年4月29日,太平洋研究员周豫,霍亮,戎晓婕发布了对益方生物的研报《贝福替尼和格索雷塞商业化推进顺利,关注TYK2i UC 2期临床》,该研报对益方生物给出“买入”评级,认为其目标价为35.28元,现价已超分析师预估,涨幅达到33.22%。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为76.07%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072900026292.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","601099"],"gpt_icon":0},{"id":"2555081024","title":"历史新高!中际旭创股价突破200元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555081024","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555081024?lang=zh_cn&edition=full","pubTime":"2025-07-29 12:40","pubTimestamp":1753764056,"startTime":"0","endTime":"0","summary":"CRO、创新药板块联手大涨,苑东生物、益方生物等个股盘中股价创历史新高。截至上午收盘,上证指数下跌0.08%,深证成指下跌0.04%,创业板指上涨0.92%。药明康德2025年中报显示,公司上半年营业收入、净利润均创下历史新高。其中,公司营业收入同比增长20.64%至207.99亿元;实现净利润85.61亿元,同比增长101.92%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072912410897249501&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072912410897249501&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688513","BK1161","BK1574","603259","603200","01276","603229","01093","601138","688382","688630","688660","02359","688313","06978","600276"],"gpt_icon":1},{"id":"2555808564","title":"益方生物-U涨5.21% 医保谈判预期博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2555808564","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555808564?lang=zh_cn&edition=full","pubTime":"2025-07-29 10:02","pubTimestamp":1753754547,"startTime":"0","endTime":"0","summary":"益方生物-U今日盘中表现强劲,截至10点01分,股价报47.05元/股,上涨5.21%。多空博弈下的资金躁动益方生物-U近期股价波动凸显资金面博弈特征。截至7月28日,主力资金单日净流入2062.9万元,但7月24日曾现单日净流出逾5000万元,多空分歧显著。医保谈判政策窗口临近,创新药企估值敏感度提升,资金对政策预期博弈加剧股价震荡。创新药企的估值重构之路益方生物-U长期估值锚定核心产品商业化进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729100237a6c6d892&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250729100237a6c6d892&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2554971473","title":"每周股票复盘:益方生物(688382)一致行动协议解除及权益变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2554971473","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554971473?lang=zh_cn&edition=full","pubTime":"2025-07-27 06:16","pubTimestamp":1753568177,"startTime":"0","endTime":"0","summary":"截至2025年7月25日收盘,益方生物报收于44.14元,较上周的45.5元下跌2.99%。本周关注点控股股东、实际控制人的一致行动人解除一致行动协议,持股比例被动稀释至27.26%公司公告汇总益方生物关于控股股东、实际控制人的一致行动人解除一致行动协议暨权益变动的提示性公告。本次权益变动前,控股股东及其一致行动人合计持有公司股份164,263,228股,持股比例为28.58%。因股权激励归属,公司总股本增加至578,327,844股,控股股东及其一致行动人持股比例被动稀释至27.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072700001132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2554780558","title":"益方生物-U股价下跌2.24% 控股股东一致行动关系解除","url":"https://stock-news.laohu8.com/highlight/detail?id=2554780558","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554780558?lang=zh_cn&edition=full","pubTime":"2025-07-25 03:01","pubTimestamp":1753383718,"startTime":"0","endTime":"0","summary":"益方生物-U7月24日股价报43.60元,较前一交易日下跌1.00元,跌幅2.24%。当日开盘价为45.14元,最高触及45.38元,最低下探43.00元,成交量为98362手,成交金额达4.30亿元。益方生物-U属于生物医药行业,专注于肿瘤和代谢疾病领域的创新药物研发。7月24日公司公告显示,部分一致行动人因协议到期解除一致行动关系。权益变动后,控股股东合计持股比例由28.58%降至27.26%。7月24日主力资金净流出5002.59万元,占流通市值的0.29%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072503114694b8e1a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072503114694b8e1a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2553868127","title":"上证580指数上涨1.3%,前十大权重包含内蒙一机等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553868127","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553868127?lang=zh_cn&edition=full","pubTime":"2025-07-24 21:49","pubTimestamp":1753364960,"startTime":"0","endTime":"0","summary":"金融界7月24日消息,上证指数低开高走,上证580指数 上涨1.3%,报1674.0点,成交额1612.23亿元。数据统计显示,上证580指数近一个月上涨10.14%,近三个月上涨12.55%,年至今上涨17.29%。据了解,上证580指数从沪市证券中选取市值规模较小、流动性较好的580只证券作为样本,反映上海证券市场市值较小上市公司证券的整体表现。该指数以2018年12月28日为基日,以1000.0点为基点。从上证580指数持仓的市场板块来看,上海证券交易所占比100.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072421571094b8732f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072421571094b8732f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688382","399300","BK0037","BK0188","BK0279","000001.SH","600331","600602","BK0000","600326","600155","688313","600259","601519","BK0010","600967","159982","600601"],"gpt_icon":0},{"id":"2553019112","title":"益方生物:控股股东、实际控制人的一致行动人解除一致行动协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2553019112","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553019112?lang=zh_cn&edition=full","pubTime":"2025-07-24 17:12","pubTimestamp":1753348358,"startTime":"0","endTime":"0","summary":"格隆汇7月24日丨益方生物公布,公司于近日收到公司控股股东香港益方、YUEHENGJIANGLLC、XINGDAILLC、实际控制人YAOLINWANG(王耀林)、YUEHENGJIANG(江岳恒)以及XINGDAI(代星),及其一致行动人LINGZHANGLLC、LINGZHANG(张灵)及YAOLINWANGLLC出具的《关于益方生物控股股东、实际控制人的一致行动人到期解除一致行动关系的通知》。本次权益变动不会导致公司控股股东、实际控制人发生变化;不会影响公司的治理结构和持续经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724171249971bad74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724171249971bad74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2553257121","title":"益方生物-U股价小幅回落 生物医药板块活跃度提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2553257121","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553257121?lang=zh_cn&edition=full","pubTime":"2025-07-23 00:30","pubTimestamp":1753201815,"startTime":"0","endTime":"0","summary":"益方生物-U最新报价44.61元,较前一交易日下跌0.84%。盘中股价波动区间为43.50元至46.83元,振幅达到7.40%,成交金额4.77亿元。该公司属于生物医药行业,专注于创新药物研发。作为上海本地企业,其业务涉及创新药领域,并入选了沪股通标的。7月22日数据显示,益方生物-U获得主力资金净流入1809.96万元,占流通市值的0.1%。当前公司总市值257.99亿元,流通市值179.02亿元。风险提示:股市有风险,投资需谨慎。本文不构成任何投资建议,投资者应独立判断并承担相应风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072300404297b0e436&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025072300404297b0e436&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","399441","688382","161726"],"gpt_icon":0},{"id":"2553035504","title":"上证580指数上涨1.17%,前十大权重包含益方生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2553035504","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553035504?lang=zh_cn&edition=full","pubTime":"2025-07-21 23:39","pubTimestamp":1753112349,"startTime":"0","endTime":"0","summary":"金融界7月21日消息,上证指数高开高走,上证580指数 上涨1.17%,报1653.03点,成交额1587.69亿元。数据统计显示,上证580指数近一个月上涨7.92%,近三个月上涨13.89%,年至今上涨15.98%。据了解,上证580指数从沪市证券中选取市值规模较小、流动性较好的580只证券作为样本,反映上海证券市场市值较小上市公司证券的整体表现。该指数以2018年12月28日为基日,以1000.0点为基点。从上证580指数持仓的市场板块来看,上海证券交易所占比100.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/07/21233951862590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["000001.SH","BK0239","399300","688382","159982"],"gpt_icon":0},{"id":"2552417535","title":"每周股票复盘:益方生物(688382)5笔大宗交易折价12.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2552417535","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552417535?lang=zh_cn&edition=full","pubTime":"2025-07-20 03:32","pubTimestamp":1752953530,"startTime":"0","endTime":"0","summary":"截至2025年7月18日收盘,益方生物报收于45.5元,较上周的36.65元上涨24.15%。限售股东3名,均为公司员工持股平台,对应的股份数量为16314684股,占公司总股本的比例为2.82%。自本次上市流通的限售股形成至本公告披露日,公司总股本变更为578327844股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072000000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2552468749","title":"7月18日益方生物-U涨6.38%,平安医疗健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2552468749","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552468749?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:19","pubTimestamp":1752826797,"startTime":"0","endTime":"0","summary":"证券之星消息,7月18日益方生物-U涨6.38%创60日新高,收盘报45.5元,换手率3.34%,成交量13.41万手,成交额5.76亿元。根据2025基金半年报公募基金重仓股数据,重仓该股的公募基金共40家,其中持有数量最多的公募基金为平安基金的平安医疗健康混合A。该公募基金现任基金经理为周思聪。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025257.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382","159760"],"gpt_icon":0},{"id":"2552468098","title":"益方生物-U涨6.38%,太平洋二个月前给出“买入”评级,目前股价已超目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2552468098","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552468098?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:19","pubTimestamp":1752826792,"startTime":"0","endTime":"0","summary":"今日益方生物-U涨6.38%,收盘报45.5元。2025年4月29日,太平洋研究员周豫,霍亮,戎晓婕发布了对益方生物的研报《贝福替尼和格索雷塞商业化推进顺利,关注TYK2i UC 2期临床》,该研报对益方生物给出“买入”评级,认为其目标价为35.28元,现价已超分析师预估,涨幅达到28.97%。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为76.07%。证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为华西证券的崔文亮。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071800025254.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601099","688382"],"gpt_icon":0},{"id":"2552484406","title":"益方生物1631万股限售股将于7月25日流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2552484406","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552484406?lang=zh_cn&edition=full","pubTime":"2025-07-17 19:35","pubTimestamp":1752752135,"startTime":"0","endTime":"0","summary":"7月17日,益方生物(688382)发布公告,本次股票上市流通总数为1631万股,上市流通日期为2025年7月25日。此次上市流通的限售股为公司首次公开发行部分限售股,限售期为自公司首次公开发行股票并在科创板上市之日起36个月。该限售股占公司总股本的比例为2.82%。公告中提到,自本次上市流通的限售股形成至公告披露日,公司因进行限制性股票激励计划归属登记,导致公司总股本由5.75亿股变更为5.78亿股。此次上市流通的限售股股东为三名公司员工持股平台,分别持有758万股、519万股和355万股,均已严格履行相关承诺。2025年一季度,益方生物实现收入819万元,归母净利润-5750万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171936149546179e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202507171936149546179e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2552010333","title":"益方生物-U涨5.00% 资金博弈与事件共振驱动估值波动","url":"https://stock-news.laohu8.com/highlight/detail?id=2552010333","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552010333?lang=zh_cn&edition=full","pubTime":"2025-07-17 13:27","pubTimestamp":1752730068,"startTime":"0","endTime":"0","summary":"益方生物-U今日股价大幅上涨,截至13点27分,最新价为42.00元/股,涨幅达5.00%。资金博弈与事件共振驱动估值波动益方生物-U近期净流入源于多重短期因素交织。截至7月15日,主力资金单日净流入7207万元后,次日即转为净流出1140万元,资金短期博弈特征显著。贝达药业1.8亿元欠款纠纷持续发酵,引发市场对合作稳定性的担忧,叠加科创50指数宽幅震荡,机构调仓进一步放大波动。当前13.72倍市净率显著高于行业中枢,反映市场对管线价值的溢价共识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717132750a450376a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717132750a450376a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688382","BK0239"],"gpt_icon":0},{"id":"2551114917","title":"贝达药业:公司与益方生物尚无其他应披露而未披露的合作事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2551114917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551114917?lang=zh_cn&edition=full","pubTime":"2025-07-16 12:48","pubTimestamp":1752641288,"startTime":"0","endTime":"0","summary":"证券之星消息,贝达药业(300558)07月16日在投资者关系平台上答复投资者关心的问题。投资者提问:请问董秘,贝达药业与益方生物的项目合作除贝福替尼外,有没有益方生物在研的其他项目进行合作?看到益方目前推进的二三期临床中有几个项目数据很好,是否有洽谈合作?贝达药业回复:您好!2018年12月,公司与益方生物就D-0316(贝福替尼)达成合作。截至目前,公司与益方生物尚无其他应披露而未披露的合作事项。如有重大合作项目,公司会及时公开披露。谢谢!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071600017645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382","300558","BK0060"],"gpt_icon":0},{"id":"2551119280","title":"科创成长层改革推进 券商系统升级及风险揭示书签署有序展开","url":"https://stock-news.laohu8.com/highlight/detail?id=2551119280","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551119280?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:13","pubTimestamp":1752635582,"startTime":"0","endTime":"0","summary":"上交所方面正组织风险揭示书签署工作,并修订相关指南,新增《科创板科创成长层企业股票投资风险揭示书必备条款》,明确未盈利企业存在的各类投资风险。上交所下发通知要求券商完善适当性管理工作,包括完成风险揭示书签署及系统准备,给予投资者充分阅读时间,并通过多种渠道开展投资者教育。上交所将持续督促券商并开展监督检查。7月14日,上交所举办专题培训会,120家券商330余名相关负责人参会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071611164495444cb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688443","688373","06160","688277","688512","688382","688327","688220","BK0239","000690.SH","688322","688549","688165","688176","688343","688221","688387","688515","688192","688266","688197","02402","688469","01877","688538","688302","09969","688280","ONC","688316","688256","688702","688561"],"gpt_icon":0},{"id":"2551572168","title":"7月15日益方生物现5笔折价12.99%的大宗交易 合计成交4920.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551572168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551572168?lang=zh_cn&edition=full","pubTime":"2025-07-15 17:20","pubTimestamp":1752571254,"startTime":"0","endTime":"0","summary":"证券之星消息,7月15日益方生物发生大宗交易,交易数据如下:近三个月该股共发生34笔大宗交易,合计成交7.15万手,折价成交34笔。该股近期无解禁股上市。截至2025年7月15日收盘,益方生物报收于38.95元,上涨7.89%,换手率5.23%,成交量20.98万手,成交额7.96亿元。该股近半年内有股东持股变动,合计净减持2537.89万股,股东增减持明细如下表:该股最近90天内共有9家机构给出评级,买入评级7家,增持评级1家;过去90天内机构目标均价为33.99。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071500029465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2551745130","title":"益方生物-U涨5.15%创历史新高 资金博弈与研发进展推动股价上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2551745130","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551745130?lang=zh_cn&edition=full","pubTime":"2025-07-15 10:55","pubTimestamp":1752548135,"startTime":"0","endTime":"0","summary":"益方生物-U今日股价大幅上涨,截至10点54分,报37.96元/股,涨幅达5.15%,创历史新高。事件催化与资金博弈益方生物-U近期股价波动受多重短期因素共振影响。贝达药业1.8亿元欠款纠纷发酵,直接引发市场对双方合作风险的担忧,叠加科创50指数宽幅震荡,机构调仓进一步加剧股价波动。近半年8家机构给予买入评级,当前12.41倍市净率显著高于行业中枢,反映市场对创新药企管线价值的溢价共识。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715105539a6aa066d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715105539a6aa066d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688382"],"gpt_icon":0},{"id":"2551188325","title":"医药主题基金首批二季报出炉!这只产品规模环比增30倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188325","media":"北京商报官方账号","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551188325?lang=zh_cn&edition=full","pubTime":"2025-07-14 18:40","pubTimestamp":1752489611,"startTime":"0","endTime":"0","summary":"公募基金二季报陆续披露中。就在前几日,长城基金也披露了旗下4只医药主题基金二季报。从规模变动来看,5只医药主题基金环比均有不同幅度的增长,其中长城医药产业精选混合型发起式的最新规模更大涨超30倍。公开资料显示,截至7月14日,已有永赢医药健康股票、长城医药产业精选混合型发起式、长城医药科技六个月持有期混合、长城医疗保健混合、长城大健康混合合计5只医药健康相关主题基金发布2025年二季报。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714184621a6a89973&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714184621a6a89973&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688382","000121.SH","BK0239","688331","688192","688068","688520","603590"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1753801736073,"stockEarnings":[{"period":"1week","weight":-0.006},{"period":"1month","weight":0.329},{"period":"3month","weight":1.0878},{"period":"6month","weight":2.4059},{"period":"1year","weight":5.2545},{"period":"ytd","weight":2.3624}],"compareEarnings":[{"period":"1week","weight":0.0107},{"period":"1month","weight":0.0507},{"period":"3month","weight":0.0947},{"period":"6month","weight":0.1069},{"period":"1year","weight":0.2446},{"period":"ytd","weight":0.0734}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"益方生物科技(上海)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10559人(较上一季度减少7.46%)","perCapita":"39550股","listingDate":"2022-07-25","address":"上海市浦东新区中国(上海)自由贸易试验区李冰路67弄4号210室","registeredCapital":"57832万元","survey":" 益方生物科技(上海)股份有限公司的主营业务是创新药物的研发、生产和销售。公司的主要产品是对外授权产品贝福替尼、对外授权产品格索雷塞、临床试验阶段产品Taragarestrant、临床试验阶段产品D-0120、临床试验阶段产品D-2570。","listedPrice":18.12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益方生物,688382,益方生物股票,益方生物股票老虎,益方生物股票老虎国际,益方生物行情,益方生物股票行情,益方生物股价,益方生物股市,益方生物股票价格,益方生物股票交易,益方生物股票购买,益方生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益方生物(688382)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益方生物(688382)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}